Clinical Trial Update: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pirtobrutinib (LOXO-305) to ibrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: Loxo Oncology, Inc. | Conditions: Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic | Phase 3 | Status: RECRUITING